This trial is testing if a painkiller can also help prevent heart problems after surgery.
- Cardiovascular Disease
- Local Anesthesia
- Atrial Fibrillation
1 Primary · 13 Secondary · Reporting Duration: 24, 48, 72, 96, and 120 hours post-operatively
2 Treatment Groups
1 of 2
1 of 2
30 Total Participants · 2 Treatment Groups
Primary Treatment: Ropivacaine 0.2% Injectable Solution · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals have been enrolled in this experiment?
"Affirmative. According to the data accessible on clinicaltrials.gov, this medical trial is open for recruitment and has been since April 9th 2021. Its last update was February 25th 2022 and a total of 30 patients are needed from one single location." - Anonymous Online Contributor
What medical maladies is Ropivacaine 0.2% Injectable Solution typically utilized to address?
"Ropivacaine 0.2% Injectable Solution is a common anaesthetic medication typically used during surgical procedures and childbirth or to manage postoperative pain." - Anonymous Online Contributor
Are new participants being accepted at this point for the experiment?
"This is accurate; clinicaltrials.gov has reported that the trial, which was initially published on April 9th 2021, is actively recruiting to fill 30 vacancies across a solitary site of recruitment." - Anonymous Online Contributor
How hazardous is Ropivacaine 0.2% Injectable Solution to patients' wellbeing?
"There is an abundance of evidence supporting the safety of Ropivacaine 0.2% Injectable Solution, thus it's been awarded a 3 on our rating scale due to its Phase 4 status." - Anonymous Online Contributor